- source: GEO
  label: GSE62116
  title: Validation of a genomic classifier that predicts metastasis following radical
    prostatectomy in at risk patient population
  accession: GSE62116
  year: 2014
  pubmed_id:
  - 23770138
  - 26246306
  - 26631616
  doi: 10.1016/j.juro.2013.06.017
  platform:
  - accession: GPL5188
    name: '[HuEx-1_0-st] Affymetrix Human Exon 1.0 ST Array [probe set (exon) version]'
    manufacturer: Affymetrix
    distribution: commercial
    technology: in situ oligonucleotide
  citation: |
    Karnes RJ, Bergstralh EJ, Davicioni E, et al.  Validation of a genomic classifier that predicts metastasis following radical  prostatectomy in an at risk patient population.  J Urol. 2013;190(6):2047-53.
  size:
    'n': 235
    comments: We generated 22-marker genomic classifier scores for 235 patients with
      available genomic data.
  link:
    primary: https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE62116
    pub: https://www.sciencedirect.com/science/article/pii/S002253471304603X
- source: GEO
  label: GSE51066
  title: A genomic classifier predicting metastatic disease progression in men with
    biochemical recurrence after prostatectomy
  accession: GSE51066
  year: 2016
  pubmed_id: 24145624
  doi: 10.1038/pcan.2013.49
  platform:
  - accession: GPL5188
    name: '[HuEx-1_0-st] Affymetrix Human Exon 1.0 ST Array [probe set (exon) version]'
    manufacturer: Affymetrix
    distribution: commercial
    technology: in situ oligonucleotide
  citation: |
    Ross AE, Feng FY, Ghadessi M, et al.  A genomic classifier predicting metastatic disease progression in men with  biochemical recurrence after prostatectomy.  Prostate Cancer Prostatic Dis. 2014;17(1):64-9.
  size:
    'n': 85
    comments: 85 clinically high-risk patients who developed biochemical recurrence
      after radical prostatectomy
  link:
    primary: https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE51066
    pub: https://www.nature.com/articles/pcan201349
- source: GEO
  label: GSE26367
  title: Protein-coding and MicroRNA Biomarkers of Recurrence of Prostate Cancer Following
    Radical Prostatectomy
  accession: GSE26367
  year: 2011
  pubmed: 21703393
  doi: 10.1016/j.ajpath.2011.03.008
  platform:
  - accession: GPL11309
    name: Illumina Custom Prostate Cancer DASL Panel 1.5K expression beadchip
    manufacturer: Illumina Inc.
    distribution: custom-commercial
    technology: oligonucleotide beads
  - accession: GPL11350
    name: Illumina Custom Prostate Cancer DASL Panel miRNA
    manufacturer: Illumina Inc.
    distribution: custom-commercial
    technology: oligonucleotide beads
  citation: |
    Long Q, Johnson BA, Osunkoya AO, et al.  Protein-coding and microRNA biomarkers of recurrence of prostate cancer following radical prostatectomy.  Am J Pathol. 2011;179(1):46-54.
  size:
    'n': 70
    comments: 70 formalin-fixed, paraffin-embedded radical prostatectomy specimens
      with known long-term outcomes
  link:
    primary: https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE26367
    pub: https://www.sciencedirect.com/science/article/pii/S000294401100321X
  comment: Superseries, includes GSE26022, GSE26242, GSE26245
- source: GEO
  label: GSE70770
  title: Prostate cancer stratification using molecular profiles
  accession: GSE70770
  year: 2015
  pubmed_id:
  - 26501111
  - 26950096
  doi: 10.1016/j.ebiom.2015.07.017
  platform:
  - accession: GPL6801
    name: '[GenomeWideSNP_6] Affymetrix Genome-Wide Human SNP 6.0 Array'
    manufacturer: Affymetrix
    distribution: commercial
    technology: in situ oligonucleotide
  - accession: GPL10558
    name: Illumina HumanHT-12 V4.0 expression beadchip
    manufacturer: Illumina Inc.
    distribution: commercial
    technology: oligonucleotide beads
  - accession: GPL16104
    name: Illumina HumanOmni2.5-8 BeadChip
    manufacturer: Illumina, Inc.
    distribution: custom-commercial
    technology: oligonucleotide beads
  - accession: GPL20641
    name: Illumina HumanOmni2.5M-8v1-1_B [data table]
    manufacturer: Illumina
    distribution: commercial
    technology: oligonucleotide beads
  citation: |
    Ross-Adams H, Lamb AD, Dunning MJ, et al.  Integration of copy number and transcriptomics provides risk stratification  in prostate cancer: A discovery and validation cohort study.  EBioMedicine. 2015;2(9):1133-44.
  size:
    'n': 808
    comments: |
      Ross-Adams (2105): 482 tumour, benign and germline samples from 259 men  with primary prostate cancer. Whitington (2016): 295 prostate cancer chromatin immunoprecipitation and sequencing experiments with genotype and gene  expression data from 602 prostate tumor samples. GEO page: 808 samples.
  link:
    primary: https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE70770
    pub: https://www.sciencedirect.com/science/article/pii/S2352396415300712
  comments: Superset, includes GSE70768, GSE70769, GSE1965
- source: GEO
  label: GSE40272
  title: Increased expression of NuSAP in recurrent prostate cancer is mediated by
    E2F1
  accession: GSE40272
  year: 2012
  pubmed_id: 22349817
  doi: 10.1038/onc.2012.27
  platform:
  - accession: GPL9497
    name: SMD Print_1529 Homo sapiens
    manufacturer: Stanford Functional Genomics Facility, Stanford School of Medicine
    distribution: non-commercial
    technology: spotted DNA/cDNA
  - accession: GPL15971
    name: SMD Print_1392 hos Homo sapiens
    manufacturer: Stanford Functional Genomics Facility, Stanford School of Medicine
    distribution: non-commercial
    technology: spotted DNA/cDNA
  - accession: GPL15972
    name: SMD Print_1540 hoaf Homo sapiens
    manufacturer: Stanford Functional Genomics Facility, Stanford School of Medicine
    distribution: non-commercial
    technology: spotted DNA/cDNA
  citation: |
    Gulzar ZG, Mckenney JK, Brooks JD.  Increased expression of NuSAP in recurrent prostate cancer is mediated by E2F1.  Oncogene. 2013;32(1):70-7.
  size:
    'n': 98
    comments: 98 prostate tumors and 52 benign adjacent prostate tissue samples with
      detailed clinical annotation
  link:
    primary: https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE40272
    pub: https://www.nature.com/articles/onc201227
- source: GEO
  label: GSE62872
  title: |
    Association of Prostate Cancer Risk Variants with Gene Expression  in Normal and Tumor Tissue
  accession: GSE62872
  pubmed_id: 25371445
  doi: 10.1158/1055-9965.EPI-14-0694-T
  year: 2014
  platform:
  - name: Affymetrix Human Gene 1.0 ST Array [Gene Symbols]
    manufacturer: Affymetrix
    distribution: custom-commercial
    accession: GPL19370
    technology: in situ oligonucleotide
  citation: |
    Penney KL, Sinnott JA, Tyekucheva S, et al.  Association of prostate cancer risk variants with gene expression in normal and tumor tissue.  Cancer Epidemiol Biomarkers Prev. 2015;24(1):255-60.
  size:
    'n': 424
    comments: |
      264 prostate tumor and 160 normal prostate tissue samples from the Health  Professionals Follow-up Study and Physicians' Health Study Prostate Tumor Cohort.
  link:
    primary: https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE62872
    pub: http://cebp.aacrjournals.org/content/24/1/255
- source: GEO
  label: GSE79021
  title: |
    Gene expression profiling of human prostate tumors identifies chromatin  remodeling as a molecular link between obesity and lethal prostate cancer
  accession: GSE79021
  pubmed_id: 27663590
  doi: 10.1158/1078-0432.CCR-16-1245
  year: 2017
  platform:
  - name: Affymetrix Human Gene 1.0 ST Array [Gene Symbols]
    manufacturer: Affymetrix
    distribution: custom-commercial
    accession: GPL19370
    technology: in situ oligonucleotide
  citation: |
    Sinnott JA, Peisch SF, Tyekucheva S, et al.  Prognostic Utility of a New mRNA Expression Signature of Gleason Score.  Clin Cancer Res. 2017;23(1):81-87.
  size:
    'n': 602
    comments: |
      Gene expression profiling was performed on 602 prostate tissue samples  (402 tumor and 200 normal) from the Health Professionals Follow-up Study  and Physicians' Health Study Prostate Tumor Cohort. This study includes  analysis of 400 samples in GSE62872.
  link:
    primary: https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE79021
    pub: https://www.ncbi.nlm.nih.gov/pubmed/27663590
- source: GEO
  label: expO, IGC 2005
  accession: GSE2109
  platform:
  - name: '[HG-U133_Plus_2] Affymetrix Human Genome U133 Plus 2.0 Array'
    manufacturer: Affymetrix
    distribution: commercial
    accession: GPL570
    technology: in situ oligonucleotide
  citation: EXpression Project for Oncology, International Genomics Consortium, www.intgen.org
  size:
    'n': 60
    comments: n=60 after subsetting to prostate
  link:
    primary: https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE2109
- source: GEO
  label: Sun, Goodison 2009
  accession: GSE25136
  pubmed_id: 19343730
  platform:
  - name: '[HG-U133A] Affymetrix Human Genome U133A Array'
    manufacturer: Affymetrix
    distribution: commercial
    accession: GPL96
    technology: in situ oligonucleotide
  citation: Sun Y, Goodison S. Optimizing molecular signatures for predicting prostate
    cancer recurrence. Prostate 2009 Jul 1;69(10):1119-27.
- source: GEO
  label: Taylor, Gerald 2010
  accession: GSE21032
  pubmed_id: 20579941
  platform:
  - name: '[HuEx-1_0-st] Affymetrix Human Exon 1.0 ST Array [probe set (exon) version]'
    manufacturer: Affymetrix
    distribution: commercial
    accession: GPL5188
    technology: in situ oligonucleotide
  citation: Taylor BS, Schultz N, Hieronymus H, Gopalan A et al. Integrative genomic
    profiling of human prostate cancer. Cancer Cell 2010 Jul 13;18(1):11-22.
- source: GEO
  label: Sboner, Andr_n 2010
  accession: GSE16560
  pubmed_id: 20233430
  platform:
  - name: "Human 6k Transcriptionally Informative Gene Panel for DASL\t"
    manufacturer: Illumina
    distribution: commercial
    accession: GPL5474
    technology: oligonucleotide beads
  citation: |
    Sboner A, Demichelis F, Calza S, Pawitan Y et al.  Molecular sampling of prostate cancer: a dilemma for predicting disease progression.  BMC Med Genomics 2010 Mar 16;3:8."
- source: GEO
  label: GSE14206
  accession: GSE14206
  pubmed_id:
  - 20479932
  - 21266046
  platform:
  - name: Agilent-012097 Human 1A Microarray (V2) G4110B (Feature Number version)
    manufacturer: Agilent
    distribution: commercial
    accession: GPL887
    technology: in situ oligonucleotide
- source: GEO
  label: Nakagawa, Jenkins 2008
  accession: GSE10645
  pubmed_id: 18846227
  platform:
  - name: DASL Human Cancer Panel by Gene
    manufacturer: Illumina
    distribution: commercial
    accession: GPL5858
    technology: oligonucleotide beads
  - name: DASL Human Cancer Panel by Gene
    manufacturer: Illumina
    distribution: commercial
    accession: GPL5873
    technology: oligonucleotide beads
  citation: Nakagawa T, Kollmeyer TM, Morlan BW, Anderson SK et al. A tissue biomarker
    panel predicting systemic progression after PSA recurrence post-definitive prostate
    cancer therapy. PLoS One 2008;3(5):e2318.
- source: GEO
  label: Arencibia, Bonnin 2009
  accession: GSE9347
  pubmed_id: 19148481
  platform:
  - name: CNIO H. sapiens 13.6k Oncochip 1
    distribution: "non-commercial\t"
    accession: GPL1998
    technology: spotted DNA/cDNA
  citation: Arencibia JM, Martên S, P_rez-Rodrêguez FJ, Bonnin A. Gene expression
    profiling reveals overexpression of TSPAN13 in prostate cancer. Int J Oncol 2009
    Feb;34(2):457-63.
- source: GEO
  label: Poisson, Chinnaiyan 2011
  accession: GSE8511
  platform:
  - name: Agilent-012391 Whole Human Genome Oligo Microarray G4112A (Feature Number
      version)
    manufacturer: Agilent
    distribution: "commercial\t"
    accession: GPL1708
    technology: in situ oligonucleotide
  title: Profiling of prostate tissues in prostate cancer progression
  year: '2011'
- source: GEO
  label: GSE7949
  accession: GSE7949
  platform:
  - name: University of Pennsylvania/Nathanson Lab_HomoSapiens_ChromosomeRegion_Virtual
    manufacturer: Weber Laboratory/School of Medicine/University of Pennsylvania
    distribution: virtual
    accession: GPL5338
    technology: other
  title: 'Prostate Adenocarcinoma: Candidate Genomic Signatures Prognostic of Biochemical
    Failure'
  year: '2007'
- source: GEO
  label: Prueitt, Ambs 2008
  accession: GSE7055
  pubmed_id: 18459106
  platform:
  - name: '[HG-U133A_2] Affymetrix Human Genome U133A 2.0 Array'
    manufacturer: Affymetrix
    distribution: "commercial\t"
    accession: GPL571
    technology: in situ oligonucleotide
  citation: Prueitt RL, Yi M, Hudson RS, Wallace TA et al. Expression of microRNAs
    and protein-coding genes associated with perineural invasion in prostate cancer.
    Prostate 2008 Aug 1;68(11):1152-64.
- source: GEO
  label: Wallace, Ambs 2008
  accession: GSE6956
  pubmed ID: 18245496
  platform:
  - name: '[HG-U133A_2] Affymetrix Human Genome U133A 2.0 Array'
    manufacturer: Affymetrix
    distribution: "commercial\t"
    accession: GPL571
    technology: in situ oligonucleotide
  citation: Wallace TA, Prueitt RL, Yi M, Howe TM et al. Tumor immunobiological differences
    in prostate cancer between African-American and European-American men. Cancer
    Res 2008 Feb 1;68(3):927-36.
- source: GEO
  label: GSE6919
  accession: GSE6919
  pubmed ID:
  - 17430594
  - 15254046
  - 15892885
  - 17071602
  platform:
  - name: '[HG_U95B] Affymetrix Human Genome U95B Array'
    manufacturer: Affymetrix
    distribution: "commercial\t"
    accession: GPL92
    technology: in situ oligonucleotide
  - name: '[HG_U95C] Affymetrix Human Genome U95C Array'
    manufacturer: Affymetrix
    distribution: "commercial\t"
    accession: GPL93
    technology: in situ oligonucleotide
  - name: '[[HG_U95Av2] Affymetrix Human Genome U95 Version 2 Array'
    manufacturer: Affymetrix
    distribution: "commercial\t"
    accession: GPL8300
    technology: in situ oligonucleotide
- source: GEO
  label: GSE6606
  accession: GSE6606
  pubmed_id:
  - 17430594
  - 15254046
  - 15892885
  - 17071602
  platform:
  - name: '[HG_U95B] Affymetrix Human Genome U95B Array'
    manufacturer: Affymetrix
    distribution: "commercial\t"
    accession: GPL92
    technology: in situ oligonucleotide
  - name: '[HG_U95C] Affymetrix Human Genome U95C Array'
    manufacturer: Affymetrix
    distribution: "commercial\t"
    accession: GPL93
    technology: in situ oligonucleotide
  - name: '[HG_U95Av2] Affymetrix Human Genome U95 Version 2 Array'
    manufacturer: Affymetrix
    distribution: "commercial\t"
    accession: GPL8300
    technology: in situ oligonucleotide
- source: GEO
  label: Stoss, Albers 2008
  accession: GSE5377
  pubmed_id: 17646850
  platform:
  - name: '[HG-Focus] Affymetrix Human HG-Focus Target Array'
    manufacturer: Affymetrix
    distribution: "commercial\t"
    accession: GSE5377
    technology: in situ oligonucleotide
  citation: Stoss O, Werther M, Zielinski D, Middel P et al. Transcriptional profiling
    of transurethral resection samples provides insight into molecular mechanisms
    of hormone refractory prostate cancer. Prostate Cancer Prostatic Dis 2008;11(2):166-72.
- source: GEO
  label: Varambally, Chinnaiyan 2005
  accession: GSE3325
  pubmed_id: 16286247
  platform:
  - name: HG-U133_Plus_2
    manufacturer: Affymetrix
    distribution: "commercial\t"
    accession: "GPL570\t"
    technology: in situ oligonucleotide
  citation: Varambally S, Yu J, Laxman B, Rhodes DR et al. Integrative genomic and
    proteomic analysis of prostate cancer reveals signatures of metastatic progression.
    Cancer Cell 2005 Nov;8(5):393-406.
  size:
    'n': 19
  link:
    primary: https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE3325
- source: GEO
  label: True, Nelson 2006
  accession: GSE5132
  pubmed_id: 16829574
  platform:
  - name: "FHCRC Human Prostate PEDB cDNA Array v4\t"
    manufacturer: FHCRC Array Facility
    distribution: non-commercial
    accession: GPL3834
    technology: spotted DNA/cDNA
  - name: FHCRC Human Prostate PEDB cDNA Array v3
    manufacturer: FHCRC Array Facility
    distribution: non-commercial
    accession: GPL3836
    technology: spotted DNA/cDNA
  citation: True L, Coleman I, Hawley S, Huang CY et al. A molecular correlate to
    the Gleason grading system for prostate adenocarcinoma. Proc Natl Acad Sci U S
    A 2006 Jul 18;103(29):10991-6.
  size:
    'n': 32
  link:
    primary: https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE5132
- source: GEO
  label: Tomlins, Chinnaiyan 2007
  accession: GSE6099
  pubmed_id: 17173048
  platform:
  - name: Chinnaiyan Human 20K Hs6
    distribution: non-commercial
    accession: GPL2013
    technology: spotted DNA/cDNA
  citation: Tomlins SA, Mehra R, Rhodes DR, Cao X et al. Integrative molecular concept
    modeling of prostate cancer progression. Nat Genet 2007 Jan;39(1):41-51.
  size:
    'n': 104
  link:
    primary: https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE6099
- source: GEO
  label: Tamura, Nakagawa 2007
  accession: GSE6811
  pubmed_id: 17545589
  platform:
  - name: YN Human 36K (sets1-8)
    manufacturer: Laboratoryof Molecular Medicine, Instutute of Medical Science, the
      University of Tokyo
    distribution: non-commercial
    accession: GPL4747
    technology: spotted DNA/cDNA
  citation: Tamura K, Furihata M, Tsunoda T, Ashida S et al. Molecular features of
    hormone-refractory prostate cancer cells by genome-wide gene expression profiles.
    Cancer Res 2007 Jun 1;67(11):5117-25.
  size:
    'n': 35
    comments: n=35 samples from HRPC patients
  link:
    primary: https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE6811
- source: GEO
  label: Setlur, Rubin 2008
  accession: GSE8402
  pubmed_id: 18505969
  platform:
  - name: Human 6k Transcriptionally Informative Gene Panel for DASL
    manufacturer: Illumina
    distribution: commercial
    accession: "GPL5474\t"
    technology: "oligonucleotide beads\t"
  citation: Setlur SR, Mertz KD, Hoshida Y, Demichelis F et al. Estrogen-dependent
    signaling in a molecularly distinct subclass of aggressive prostate cancer. J
    Natl Cancer Inst 2008 Jun 4;100(11):815-25.
  size:
    'n': 472
  link:
    primary: https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE8402
- source: GEO
  label: Lapointe, Pollack 2004
  accession: GSE3933
  pubmed_id: 14711987
  doi: 10.1073/pnas.0304146101
  platform:
  - name: SHBB
    manufacturer: Stanford Functional Genomics Facility, Stanford School of Medicine
    distribution: non-commercial
    accession: GPL2695
    technology: spotted DNA/cDNA
  - name: SHCQ
    manufacturer: Stanford Functional Genomics Facility, Stanford School of Medicine
    distribution: non-commercial
    accession: GPL3044
    technology: spotted DNA/cDNA
  - name: SHBW
    manufacturer: Stanford Functional Genomics Facility, Stanford School of Medicine
    distribution: non-commercial
    accession: GPL3289
    technology: spotted DNA/cDNA
  citation: |
    Lapointe J, Li C, Higgins JP, van de Rijn M et al. Gene expression profiling identifies clinically relevant subtypes of prostate cancer. Proc Natl Acad Sci U S A 2004 Jan 20;101(3):811-6.
  size:
    'n': 62
    comments: n=62 primary, n=42 normal, n=9 lymph
  link:
    primary: https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE3933
- source: GEO
  label: Best, Chuaqui 2005
  accession: GSE2443
  pubmed_id: 16203770
  platform:
  - name: HG-U133A
    manufacturer: Affymetrix
    distribution: commercial
    accession: GPL96
    technology: in situ oligonucleotide
  citation: Best CJ, Gillespie JW, Yi Y, Chandramouli GV et al. Molecular alterations
    in primary prostate cancer after androgen ablation therapy. Clin Cancer Res 2005
    Oct 1;11(19 Pt 1):6823-34.
  size:
    'n': 20
  link:
    primary: https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE2443
- source: GEO
  label: Barwick, Abramovitz 2010
  accession: GSE18655
  pubmed_id: 20068566
  platform:
  - name: DASL Human Cancer Panel by Gene
    manufacturer: Illumina
    distribution: commercial
    accession: GPL5858
    technology: oligonucleotide beads
  citation: Barwick BG, Abramovitz M, Kodani M, Moreno CS et al. Prostate cancer genes
    associated with TMPRSS2-ERG gene fusion and prognostic of biochemical recurrence
    in multiple cohorts. Br J Cancer 2010 Feb 2;102(3):570-6.
  size:
    'n': 139
    comments: n=139, DASL=502 genes
  link:
    primary: https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE18655
- source: GEO
  label: Chandran, Monzon 2007
  accession: GSE6752
  pubmed_id: 17430594
  platform:
  - name: GE Healthcare/Amersham Biosciences CodeLink UniSet Human 20K I Bioarray
    manufacturer: GE Healthcare
    distribution: commercial
    accession: GPL2891
    technology: spotted oligonucleotide
  citation: Chandran UR, Ma C, Dhir R, Bisceglia M et al. Gene expression profiles
    of prostate cancer reveal involvement of multiple molecular pathways in the metastatic
    process. BMC Cancer 2007 Apr 12;7:64.
  size:
    'n': 24
    comments: n=24 samples from 4 patients (multiple metastatic samples)
  link:
    primary: https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE6752
- source: cBioportal
  label: PRAD MICH, Nature 2012
  size:
    'n': 10
  platform:
  - technology: RNAseq
  link:
    primary: http://www.cbioportal.org/study?id=prad_mich#summary
    data: http://download.cbioportal.org/prad_mich.tar.gz
- source: cBioportal
  label: PRAD FHCRC, Nat Med 2016
  size:
    'n': 171
  platform:
  - technology: microarray
  link:
    primary: http://www.cbioportal.org/study?id=prad_fhcrc#summary
    data: http://download.cbioportal.org/prad_fhcrc.tar.gz
- source: cBioportal
  label: PRAD Broad, Nat Gen 2012
  size:
    'n': 31
  platform:
  - technology: microarray
  link:
    primary: http://www.cbioportal.org/study?id=prad_broad#summary
    data: http://download.cbioportal.org/prad_broad.tar.gz
  comments: overlaps with PRAD Broad Cell 2013?
- source: cBioportal
  label: PRAD Broad, Cell 2013
  size:
    'n': 16
  platform:
  - technology: microarray
  link:
    primary: http://www.cbioportal.org/study?id=prad_broad_2013#summary
    data: http://download.cbioportal.org/prad_broad_2013.tar.gz
- source: cBioportal
  label: SU2C/PCF Dream Team, Cell 2015
  size:
    'n': 118
  platform:
  - technology: RNAseq
  link:
    primary: http://www.cbioportal.org/study?id=prad_su2c_2015#summary
    data: http://download.cbioportal.org/prad_su2c_2015.tar.gz
- source: cBioportal
  label: TCGA, Cell 2015
  pubmed_id: 26544944
  doi: 10.1016/j.cell.2015.10.025
  size:
    'n': 333
  platform:
  - technology: RNAseq
  link:
    primary: http://www.cbioportal.org/study?id=prad_tcga_pub#summary
    data: http://download.cbioportal.org/prad_tcga_pub.tar.gz
- source: ArrayExpress
  label: Kamoun et al.
  size:
    'n': 132
  link:
    primary: https://www.ebi.ac.uk/arrayexpress/experiments/E-MTAB-6131/
- source: ArrayExpress
  label: Liu et al. 2006
  size:
    'n': 57
  platform:
  - name: Affy U133
  link:
    primary: https://www.ebi.ac.uk/arrayexpress/experiments/E-TABM-26/
- source: Unknown
  label: Liu P, Moreno CS 2006
  title: |
    Sex-Determining Region Y Box 4 Is a Transforming Oncogene in  Human Prostate Cancer Cells
  pubmed_id: 16618720
  doi: 10.1158/0008-5472.CAN-05-3055
  platform:
  - name: '[HG-U133A] Affymetrix Human Genome U133A Array'
    manufacturer: Affymetrix
    distribution: commercial
    accession: GPL96
    technology: in situ oligonucleotide
  - name: '[HG-U133A] Affymetrix Human Genome U133B Array'
    manufacturer: Affymetrix
    distribution: commercial
    accession: GPL97
    technology: in situ oligonucleotide
  citation: |
    Liu P, Ramachandran S, Ali Seyed M, Scharer CD, Laycock N, Dalton WB, Williams H, Karanam S, Datta MW, Jaye DL, Moreno CS Cancer Res. 2006 Apr 15;66(8):4011-9
  link:
    pub: http://cancerres.aacrjournals.org/content/66/8/4011
